Suppr超能文献

Bace1 缺失可逆转 AD 小鼠的癫痫样活动和睡眠-觉醒障碍。

Bace1 Deletion in the Adult Reverses Epileptiform Activity and Sleep-wake Disturbances in AD Mice.

机构信息

Department of Neuroscience, University of Connecticut Health Center, Farmington, Connecticut 06030.

Department of Neuroscience, University of Connecticut Health Center, Farmington, Connecticut 06030

出版信息

J Neurosci. 2023 Aug 30;43(35):6197-6211. doi: 10.1523/JNEUROSCI.2124-22.2023. Epub 2023 Aug 3.

Abstract

Alzheimer's disease (AD) increases the risk for seizures and sleep disorders. We show here that germline deletion of β-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE1) in neurons, but not in astrocytes, increased epileptiform activity. However, deletion at adult ages did not alter the normal EEG waveform, indicating less concern for BACE1 inhibition in patients. Moreover, we showed that deletion of in the adult was able to reverse epileptiform activity in 5xFAD mice. Intriguingly, treating 5xFAD and APP (APP KI) mice of either sex with one BACE1 inhibitor Lanabecestat (AZD3293) dramatically increased epileptiform spiking, likely resulting from an off-target effect. We also monitored sleep-wake pathologies in these mice and showed increased wakefulness, decreased non-rapid eye movement sleep, and rapid eye movement sleep in both 5xFAD and APP KI mice; BACE1 inhibition in the adult 5xFAD mice reversed plaque load and sleep disturbances, but this was not seen in APP KI mice. Further studies with and without BACE1 inhibitor treatment showed different levels of plaque-associated microgliosis and activated microglial proteins in 5xFAD mice compared with APP KI mice. Together, BACE1 inhibition should be developed to avoid off-target effect for achieving benefits in reducing epileptic activity and sleep disturbance in Alzheimer's patients. BACE1 is widely recognized as a therapeutic target for treating Alzheimer's disease patients. However, BACE1 inhibitors failed in clinical trials because of inability to show cognitive improvement in patients. Here we show that BACE1 inhibition actually reduces sleep disturbances and epileptic seizures; both are seen in AD patients. We further showed that one of clinically tested BACE1 inhibitors does have off-target effects, and development of safer BACE1 inhibitors will be beneficial to AD patients. Results from this study will provide useful guidance for additional drug development.

摘要

阿尔茨海默病(AD)会增加癫痫发作和睡眠障碍的风险。我们在这里表明,神经元中β-淀粉样前体蛋白(APP)裂解酶-1(BACE1)的种系缺失,但不是星形胶质细胞,会增加癫痫样活动。然而,在成年时的缺失并没有改变正常的脑电图波形,这表明在患者中对 BACE1 抑制的担忧较小。此外,我们表明成年时的缺失能够逆转 5xFAD 小鼠的癫痫样活动。有趣的是,用一种 BACE1 抑制剂 Lanabecestat(AZD3293)治疗 5xFAD 和 APP(APP KI)小鼠的任一种性别,都会显著增加癫痫样尖峰,可能是由于脱靶效应。我们还监测了这些小鼠的睡眠-觉醒病理,并显示 5xFAD 和 APP KI 小鼠的觉醒增加,非快速眼动睡眠减少,快速眼动睡眠减少;成年 5xFAD 小鼠的 BACE1 抑制逆转了斑块负荷和睡眠障碍,但在 APP KI 小鼠中没有观察到。进一步的有和没有 BACE1 抑制剂治疗的研究表明,与 APP KI 小鼠相比,5xFAD 小鼠的斑块相关小胶质细胞增生和激活的小胶质细胞蛋白水平不同。总之,为了避免脱靶效应,应该开发 BACE1 抑制剂,以在减少阿尔茨海默病患者的癫痫活动和睡眠障碍方面获得益处。BACE1 被广泛认为是治疗阿尔茨海默病患者的治疗靶点。然而,由于无法在患者中显示认知改善,BACE1 抑制剂在临床试验中失败。在这里,我们表明 BACE1 抑制实际上会减少睡眠障碍和癫痫发作;这两种情况都出现在 AD 患者中。我们进一步表明,一种经过临床测试的 BACE1 抑制剂确实有脱靶效应,开发更安全的 BACE1 抑制剂将有益于 AD 患者。这项研究的结果将为进一步的药物开发提供有用的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8942/10476643/225a2e7b26ea/SN-JNSJ230496F001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验